Gyre Therapeutics, Inc. financial data

Symbol
GYRE on Nasdaq
Industry
Pharmaceutical Preparations
Location
12770 High Bluff Drive, Suite 150, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
CATALYST BIOSCIENCES, INC. (to 10/27/2023), TARGACEPT INC (to 8/19/2015)
Latest financial report
10-K - Q4 2024 - Mar 17, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 340 % +27.5%
Quick Ratio 33.6 %
Debt-to-equity 47.1 %
Return On Equity 18.9 %
Return On Assets 14.5 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 93.6M shares +9.59%
Common Stock, Shares, Outstanding 86.3M shares +12.7%
Entity Public Float 83.3M USD +650%
Common Stock, Value, Issued 86K USD +11.7%
Weighted Average Number of Shares Outstanding, Basic 85.1M shares +29.3%
Weighted Average Number of Shares Outstanding, Diluted 102M shares +55.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 106M USD -6.78%
Research and Development Expense 12M USD -12.7%
Selling and Marketing Expense 57.5M USD -5.97%
General and Administrative Expense 16.1M USD +9.87%
Costs and Expenses 89.6M USD -50.4%
Operating Income (Loss) 16.2M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 23.2M USD
Income Tax Expense (Benefit) 5.32M USD -37.5%
Net Income (Loss) Attributable to Parent 17.9M USD
Earnings Per Share, Basic 0.14 USD/shares
Earnings Per Share, Diluted 0.05 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 11.8M USD -64.7%
Cash, Cash Equivalents, and Short-term Investments 33.5M USD +54.4%
Accounts Receivable, after Allowance for Credit Loss, Current 19.6M USD +29.2%
Inventory, Net 6.34M USD +48%
Other Assets, Current 1.44M USD +37.4%
Assets, Current 64.8M USD +13.2%
Deferred Income Tax Assets, Net 5.62M USD +19.7%
Property, Plant and Equipment, Net 23.9M USD +2.54%
Operating Lease, Right-of-Use Asset 1.82M USD +272%
Other Assets, Noncurrent 3.03M USD +205%
Assets 125M USD +7.61%
Accounts Payable, Current 108K USD -69.6%
Contract with Customer, Liability, Current 61K USD +56.4%
Liabilities, Current 19.5M USD -2.65%
Operating Lease, Liability, Noncurrent 885K USD +345%
Other Liabilities, Noncurrent 7K USD -85.7%
Liabilities 27M USD -29.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -2.6M USD -58%
Retained Earnings (Accumulated Deficit) -73.5M USD +14.1%
Stockholders' Equity Attributable to Parent 63.3M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 98.4M USD +605%
Liabilities and Equity 125M USD +7.61%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 2.88M USD -72.3%
Net Cash Provided by (Used in) Financing Activities 658K USD
Net Cash Provided by (Used in) Investing Activities -7.22M USD +5.6%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 86.3M shares +12.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.72M USD -225%
Deferred Tax Assets, Valuation Allowance 65.6M USD +2.87%
Deferred Tax Assets, Gross 71.6M USD +4.27%
Operating Lease, Liability 1.6M USD +291%
Payments to Acquire Property, Plant, and Equipment 231K USD -86.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 11.1M USD +98.3%
Lessee, Operating Lease, Liability, to be Paid 1.69M USD +289%
Property, Plant and Equipment, Gross 29.5M USD +6.99%
Operating Lease, Liability, Current 713K USD +240%
Lessee, Operating Lease, Liability, to be Paid, Year Two 631K USD +513%
Lessee, Operating Lease, Liability, to be Paid, Year One 782K USD +246%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 94K USD +262%
Lessee, Operating Lease, Liability, to be Paid, Year Three 279K USD +163%
Deferred Tax Assets, Operating Loss Carryforwards 41.7M USD +2.57%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 1.88M USD 0%
Operating Lease, Payments 139K USD +9.45%
Additional Paid in Capital 136M USD +99.7%
Amortization of Intangible Assets 38K USD -62%
Depreciation, Depletion and Amortization 415K USD +50.4%
Deferred Tax Assets, Net of Valuation Allowance 5.62M USD +19.7%
Share-based Payment Arrangement, Expense 831K USD -88.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%